AFM
PMCB icon

Anson Funds Management’s PharmaCyte Biotech PMCB Stock Holding History

Anson Funds Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-193,400
Closed -$484K – 411
2021
Q4 		$484K Buy
+193,400
New +$533K 0.05% 251

Other funds holding PMCB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Anson Funds Management's PMCB Position: Q1 2022 in Review

Anson Funds Management sold out of PharmaCyte Biotech (PMCB) in Q1 2022, closing a stake of 193,400 shares — an estimated $484K sold.

Anson Funds Management first reported a position in PMCB in Q4 2021 and held it in 1 quarter. The position peaked at $484K in Q4 2021. 25 funds tracked by Wall St. Rank hold PMCB as of Q1 2022.

  • Anson Funds Management reported no remaining PharmaCyte Biotech position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 193,400 PharmaCyte Biotech shares in Q1 2022, an estimated $484K.
  • Anson Funds Management first reported a position in PharmaCyte Biotech in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's PharmaCyte Biotech position peaked at $484K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.